Half-strength citrate CPD and new additive solutions for improved blood preservation. I. Studies of six experimental solutions.
Poor stability of plasma factor VIII in whole blood and loss of erythrocyte 2,3-bis-phosphoglycerate (BPG) during red cell storage are limitations with systems for blood component preparation in current use. This study presents attempts to improve post-collection storage conditions in both these respects using half-strength citrate CPD solution (0.5CPD) for blood collection, which has been shown by others to improve the stability of factor VIII, and some compositions of hypotonic additive solutions for red cell storage containing citrate, adenine, mannitol, and phosphate. Guanosine was also included in some of the media. The erythrocyte BPG concentration was maintained at a normal level for 3-4 weeks with the best of the tested compositions. Total adenine nucleotide concentration was maintained at the original level for 49 days and adenosine triphosphate for 28 days. Spontaneous storage haemolysis was low, 0.31% (mean) +/- 0.08-0.10% (SD) after 49 days in the two best compositions. The intracellular pH was 0.2-0.3 pH units higher than the extracellular pH at the beginning of storage, but this difference gradually diminished and disappeared after 4-5 weeks. We suggest two likely explanations of the effects: the maintenance of intracellular pH at a level sufficiently high not to impair BPG synthesis until after several weeks of storage, and a sufficient supply of phosphate needed in the synthesis of organic phosphate compounds. The content of citrate was selected such that the total amount supplied to a patient in a massive transfusion, when using a combination of 0.5CPD plasma and red cell suspension, would be smaller than that provided by a transfusion of CPD whole blood.
Department of Clinical Immunology and Transfusion Medicine, University Hospital, Uppsala, Sweden.
C F
CF
Högman
L
L
Eriksson
J
J
Gong
J M
JM
Payrat
J
J
Debrauwere
D019794:2,3-Diphosphoglycerate; D000227:Adenine Nucleotides / Q000097:blood; D000255:Adenosine Triphosphate / Q000097:blood; D000925:Anticoagulants; D001793:Blood Preservation / Q000379:methods*; D002951:Citrates; D004163:Diphosphoglyceric Acids / Q000097:blood; D004912:Erythrocytes / Q000378:metabolism; D005947:Glucose; D006461:Hemolysis / Q000502:physiology; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007038:Hypotonic Solutions; D009994:Osmolar Concentration; D012996:Solutions
D000227:Adenine Nucleotides; D000925:Anticoagulants; D002951:Citrates; D004163:Diphosphoglyceric Acids; D007038:Hypotonic Solutions; D012996:Solutions; D019794:2,3-Diphosphoglycerate; C007077:citrate phosphate dextrose; D000255:Adenosine Triphosphate; D005947:Glucose